Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease - are we on the right road?. N Engl J Med 2014;370:377-8. [Ref.ID 97062]

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Bejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear R, for the Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33. [Ref.ID 97061]

The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. [Ref.ID 87096]

Pérez-Jiménez F. Polimorfismos de la apoproteína E y respuesta a las estatinas. Med Clin (Barc) 2008;130:413-4. [Ref.ID 82629]

Hattersley AT, McCarthy MI. What makes a good genetic association study?. Lancet 2005;366:1315-23. [Ref.ID 75011]

Blacker DJ et al. Mild cognitive impairment - no benefit from vitamin E, little from donepezil. N Engl J Med 2005;352:2439-41. [Ref.ID 74032]

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey AS, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88. [Ref.ID 74029]

Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-47. [Ref.ID 71009]

Wheeler J, Keavney B, Watkins H, Collins R, Danesh J. Paraoxonase polymorphisms and coronary heart disease. Authors' reply. Lancet 2004;364:580. [Ref.ID 71001]

Durrington PN, Mackness B, Mackness MI. Paraoxonase polymorphisms and coronary heart disease. Lancet 2004;364:579-80. [Ref.ID 71000]

Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363:1139-46. [Ref.ID 69705]

Stöllberger C, Finsterer J. Atherosclerosis: infection-induced involvement of mitochondrial chaperonins. Lancet 2003;362:1949-50. [Ref.ID 68464]

Alfonso P, Cenarro A, Pérez-Calvo J I, Puzo J, Giralt M, Giraldo P, Pocoví M. Efecto del tratamiento enzimático sustitutivo sobre el perfil lipídico en pacientes con enfermedad de Gaucher. Med Clin (Barc) 2003;120:641-6. [Ref.ID 66255]

Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001;358:115-9. [Ref.ID 57733]

Wang XL, Mahaney MC. Genotype-specific effects of smoking on risk of CHD. Lancet 2001;358:87-8. [Ref.ID 57728]

Guo Z, Fratiglioni L, Viitanen M, Lannfelt L, Basun H, Fastbom J, Winblad B. Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication?. Am J Epidemiol 2001;153:225-31. [Ref.ID 55100]

Traber MG, Jialal I. Measurement of lipid-soluble vitamins - Further adjustment needed?. Lancet 2000;355:2013-4. [Ref.ID 51382]

Larkin M. APOE-e4 foils oestrogen's effects on cognitive decline. Lancet 2000;355:1889. [Ref.ID 51134]

Sacco RL. Lobar intracerebral hemorrhage. N Engl J Med 2000;342:276-9. [Ref.ID 49059]

Haan MN, Shemanski L, Jagust W, Manolio TA, Kuller L. The role of APOE E4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40-6. [Ref.ID 45505]